Literature DB >> 15069553

Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy.

Jian Zhang1, Rui Sun, Haiming Wei, Jianhua Zhang, Zhigang Tian.   

Abstract

NK-92 cells are effective against a broad range of malignant targets both in vitro and in vivo. Stem cell factor (SCF) is an important early acting cytokine for NK cell development. The characterization and implication in clinic of SCF gene-modified NK-92 cells need to be investigated. SCF cDNA was inserted into pcDNA3 eukaryotic expression vector and the recombinant vector (pcDNA3-SCF) was transfected into NK-92 cells. The SCF gene-modified NK-92 cells (NK92-SCF) were cloned and characterized by cytokine gene expression, proliferation potential, cytotoxic function and surface phenotype. NK92-SCF cells continuously produced a high level of SCF in culture supernatant, which made the cells proliferate significantly more rapidly in response to IL-2 or IL-15 stimulation, the cumulative amount of cells in long-term culture was significantly higher. NK92-SCF cells exerted stronger cytotoxicity against a broad range of target tumor cells than their parent NK-92 cells, which was correlated to the increased expression of cytotoxic effector molecules such as perforin and Fas ligand. NK92-SCF cells became more heterogeneous; the CD56(High) and CD56(Low) subsets appeared, which may, at least partly, explain the increased proliferating and cytotoxic potential of NK92-SCF cells. SCF gene-modified NK-92 cells (NK92-SCF cells) are more promising than their parent cells for adoptive cellular immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15069553

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.

Authors:  Wen Jiang; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-08       Impact factor: 4.553

Review 2.  Natural killer cell lines in tumor immunotherapy.

Authors:  Min Cheng; Jian Zhang; Wen Jiang; Yongyan Chen; Zhigang Tian
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

Review 3.  Advances in NK cell production.

Authors:  Fang Fang; Siqi Xie; Minhua Chen; Yutong Li; Jingjing Yue; Jie Ma; Xun Shu; Yongge He; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-05       Impact factor: 22.096

Review 4.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

5.  Human interleukin-15 improves engraftment of human T cells in NOD-SCID mice.

Authors:  Anyuan Sun; Haiming Wei; Rui Sun; Weihua Xiao; Yongguang Yang; Zhigang Tian
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 6.  Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.

Authors:  Mattias Carlsten; Richard W Childs
Journal:  Front Immunol       Date:  2015-06-10       Impact factor: 7.561

Review 7.  A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.

Authors:  Dong-Sup Chung; Hye-Jin Shin; Yong-Kil Hong
Journal:  J Immunol Res       Date:  2014-06-09       Impact factor: 4.818

Review 8.  Role of Natural Killer Cells in HIV-Associated Malignancies.

Authors:  Fabio E Leal; Thomas A Premeaux; Mohamed Abdel-Mohsen; Lishomwa C Ndhlovu
Journal:  Front Immunol       Date:  2017-03-21       Impact factor: 7.561

Review 9.  Nonviral genome engineering of natural killer cells.

Authors:  Gabrielle M Robbins; Minjing Wang; Emily J Pomeroy; Branden S Moriarity
Journal:  Stem Cell Res Ther       Date:  2021-06-16       Impact factor: 6.832

10.  Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.

Authors:  Congcong Zhang; Pranav Oberoi; Sarah Oelsner; Anja Waldmann; Aline Lindner; Torsten Tonn; Winfried S Wels
Journal:  Front Immunol       Date:  2017-05-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.